Edwards Lifesciences (EW) Accumulated Expenses (2009 - 2026)

Edwards Lifesciences' Accumulated Expenses history runs 18 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 0.6% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 0.6% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 21.78% from the prior year.
• Accumulated Expenses slipped to $1.2 billion in Q1 2026 per EW's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Accumulated Expenses topped out at $1.7 billion in Q3 2024 and bottomed at $739.5 million in Q3 2022.
• The 5-year median for Accumulated Expenses is $939.9 million (2023), against an average of $1.1 billion.
• Across the five-year window, Accumulated Expenses soared 70.44% in 2024 and dropped 20.13% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $795.0 million in 2022, then grew by 7.72% to $856.4 million in 2023, then surged by 49.74% to $1.3 billion in 2024, then grew by 21.78% to $1.6 billion in 2025, then decreased by 22.93% to $1.2 billion in 2026.
• Per Business Quant, the three latest EW Accumulated Expenses figures stand at $1.2 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.4 billion (Q3 2025).